Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu 177 dotatate + lutetium Lu 177 vipivotide tetraxetan
- Development stage
- Unknown
- Lead developer
- Advanced Accelerator Applications
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
This is a combination of two radiopharmaceutical cancer therapies, each containing the radioactive isotope lutetium-177 but conjugated to different targeting molecules. **Lutathera** (lutetium Lu 177 dotatate) is a peptide receptor radionuclide therapy (PRRT) that targets somatostatin receptors on gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It binds to somatostatin receptor-positive tumor cells and delivers targeted radiation, leading to cell death[2][7]. **Pluvicto** (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapy that targets prostate-specific membrane antigen (PSMA), which is highly expressed on metastatic castration-resistant prostate cancer cells. By binding PSMA, it delivers localized radiation to these cancer cells[3][4][5][8]. Both drugs are administered intravenously in cycles and are approved for their respective indications.
- Other names
- lutetium Lu 177 dotatate + lutetium Lu 177 vipivotide tetraxetan
02
Targets
PSMA (Prostate-specific membrane antigen)SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on lutetium Lu 177 dotatate + lutetium Lu 177 vipivotide tetraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu 177 dotatate + lutetium Lu 177 vipivotide tetraxetan.